# Ottava: robot model

Canonical ID: `d78c50a9-6fd6-4296-9254-9f66d2360efb`

- **Slug:** jnj-ottava
- **Form factor:** surgical
- **Maturity stage:** research
- **Lifecycle:** active
- **Deployments registered:** 0

## Specs

- **notes:** [object Object],[object Object],[object Object],[object Object]
- **products:** Ottava: J&J MedTech (Ethicon) soft-tissue general-surgery robotic platform, four arms integrated into the operating table; announced 2020. NOT cleared, NOT marketed.
- **formFactor:** surgical (unified-architecture four-arm soft-tissue general-surgery robot; arms integrated into the table)

## Deployments

_No deployments registered for this model._

## Supply chain

_No verified supply relationships on file. Supply-chain coverage is being added across the registry; check back as the seed populates this model's suppliers._

_Suppliers appear when verified with at least two strong sources. Sources are append-only; corrections add new sources rather than rewrite history._

## Common questions

### What is Ottava?

Johnson & Johnson (NYSE: JNJ; founded 1886, New Brunswick, New Jersey), through its MedTech and Ethicon division, is developing Ottava, a soft-tissue general-surgery robotic platform with a unified architecture of four arms integrated into the operating table, announced in 2020 and repeatedly delayed. The critical audit finding is that as of mid-2026 Ottava is pre-market: J&J submitted it to the FDA via a De Novo classification application on January 7, 2026 for multiple upper-abdomen general-surgery procedures, and the company's own language states it is under development and not authorized to be marketed or sold in any market. Investigational first cases were completed in early 2025 at Memorial Hermann in the Texas Medical Center, with a second investigational study for inguinal hernia approved in late 2025. The registry records Ottava at research maturity, because under the verified-vs-claimed framework no regulatory clearance means research-tier regardless of corporate scale or demonstrations, and Ottava has no clearance and zero installed base, only investigational-trial cases. An aggregator claim that Ottava was targeted for commercial launch in late 2025 or early 2026 is contradicted by the primary J&J source and is not registered. For context, J&J's separate Monarch robotic bronchoscopy, acquired through Auris in 2019, and its Velys robotic knee-replacement system are already FDA-cleared commercial products, but Ottava is the soft-tissue surgical-robot entity and remains pre-market.

### Who makes Ottava?

Ottava is made by Johnson & Johnson, based in New Brunswick, New Jersey, USA, founded in 1886.

### Where is Ottava deployed?

No verified deployments of Ottava are currently on the DEPLOY registry. DEPLOY records deployments only when verified at a named site with a primary source; absence may reflect pre-deployment, research, or manufacturer-internal use.

### What is Ottava's maturity stage?

Ottava is at the research stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Research stage means active development without commercial deployments on file.


## Sources (3)

1. https://www.jnj.com/media-center/press-releases/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration
2. https://www.medtechdive.com/news/jnj-layoffs-auris-california-robotic/644544/
3. https://www.fiercebiotech.com/medtech/jj-to-take-over-verb-surgical-its-robotics-venture-verily

_API: GET /v1/models/d78c50a9-6fd6-4296-9254-9f66d2360efb · canonical URL: /models/jnj-ottava_